SCIESCOPUSQ2
PULMONARY PHARMACOLOGY & THERAPEUTICS
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, United States
PULMONARY PHARMACOLOGY & THERAPEUTICS is an academic journal published by ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD (United States). Identifiers: ISSN 1094-5539, eISSN 1522-9629. Indexed in SCIE, SCOPUS. Metrics: JIF 2.8, CiteScore 6.6, SJR 0.790, SNIP 0.76. Subject areas: PHARMACOLOGY & PHARMACY, RESPIRATORY SYSTEM. tlooto lists 2,110 papers from this journal.
CiteScore
6.60
Scopus citation metric
SJR
0.790
SCImago rank
SNIP
0.76
Source normalized impact
Percentage rank
-
JIF percentile rank
Journal profile
- ISSN
- 1094-5539
- eISSN
- 1522-9629
- Abbreviation
- PULM PHARMACOL THER
- Publisher
- ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
- Country
- United States
Web of Science categories
SCIEPHARMACOLOGY & PHARMACY, RESPIRATORY SYSTEM
Scopus ASJC categories
2704 Biochemistry (medical)2736 Pharmacology (medical)2740 Pulmonary and Respiratory Medicine
Keywords
Pharmacology & Pharmacy | Respiratory System
Papers in this journal
Recent papers
- Effectiveness of Mepolizumab and Dupilumab in Patients with Asthma-COPD Overlap (ACO) compared to Severe Uncontrolled Asthma: A Retrospective Observational Cohort Study.
2026 · 1 citations
- TROP2 as a Promising Therapeutic Target in Lung Cancer: Current Clinical Trial Landscape and Future Directions.
2026
- Brain-derived neurotrophic factor (BDNF) signaling in respiratory disease: Mechanisms, neuroimmune crosstalk, and therapeutic implications
2026
- PD05, a novel neutrophil elastase inhibitor, mitigates LPS-induced acute lung injury in a preclinical model
2026
- m6A reader IGF2BP2 mediates airway remodeling by stabilizing Dixdc1 in asthma pathogenesis
2026
Most cited papers
- Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway.
2008 · 340 citations
- Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review.
2007 · 316 citations
- The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
2010 · 308 citations
- Reactive oxygen species as mediators in asthma.
2001 · 299 citations
- The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.
2010 · 256 citations